Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
18.44%
Operating Margin
14.33%
Net Margin
9.47%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
16.49%
Income Tax Rate
26.34%
EPS
6.9100000000
Balance Sheet Analysis
Current Ratio
0.95
Cash Ratio
0.27
Working Capital
$-861.80M
Debt to Equity
1.80
Debt to Assets
23.19%
Equity Ratio
12.89%
Cash Flow Analysis
Operating Cash Flow Ratio
9.68%
Free Cash Flow Ratio
9.14%
CapEx to Revenue
0.53%
Dividends Paid
$562.70M
Stock Buybacks
$570.80M
Total Shareholder Returns
$1.13B
Cash Position Change
3.51%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Detailed Growth Metrics
Core Performance
Revenue
2.82%
Net Income
7.08%
EPS
7.97%
Operating Income
1.03%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
4.02%
Operating Cash Flow
53.47%
Free Cash Flow
58.38%
Balance Sheet Health
Assets
3.86%
Debt
0.15%
Book Value per Share
13.90%
Inventory
7.01%
Shareholder Returns
Dividends per Share
-1.13%
Shares Outstanding
-2.06%
Long Term Trends
3Y Revenue/Share
19.44%
5Y Revenue/Share
8.13%
3Y Dividend/Share
7.07%
5Y Dividend/Share
15.45%